Poland· PL-100507614
Versatis
A lidocaine product containing lidocainum, registered in Poland by Delfarma Sp. z o.o.. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Lidocaine is registered in 11 of 19 countries.
Countries holding a registration under ATC N01BB02 (lidocaine), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Lidocaine · ATC N01BB02
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Lidocainum
- Manufacturer
- Delfarma Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- N01BB02
- ATC class
- Lidocaine
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 5
- gtin05909991557904
- gtin05909991557911
- gtin05909991557928
- gtin05909991557935
- gtin05909991557942
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
671 interactions on record for lidocaine.
Graded by severity as the source publishes them — 13 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lidocaine · interactions on record
671 records
- 13 severe
- 206 moderate
- 79 minor
- 373 info
Most severe, free to view
- DofetilideC01BD04severe
- ArbutamineC01CA22severe
- ConivaptanC03XA02severe
- SaquinavirJ05AE01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under N01BB02
Lidocaine, as other registers publish it.
- Ireland1% w/v Lidocaine Hydrochloride Injection BPB. Braun Melsungen AG
- Ireland2% w/v Lidocaine Hydrochloride Injection BPB. Braun Melsungen AG
- BelgiumAngiocine 1.5 mg - 5 mgCeres Pharmaceuticals
- PolandBobodentPrzedsiębiorstwo Produkcji Farmaceutycznej HASCO-LEK S.A.
- PolandBravera ControlAflofarm Farmacja Polska Sp. z o.o.
- CanadaCATHEJELLPHARMAZEUTISCHE FABRIK MONTAVIT GES M.B.H.
- BelgiumCathejell 20 mg/g - 0.5 mg/gPharmazeutische Fabrik Montavit
- NetherlandsDentinox Suikervrij, oplossing voor dentaal gebruik 3,8 mg/mlDentinox Gesellschaft fuer pharmazeutische Praeparate Lenk & Schuppan KG
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dd4446a6-58cb-498d-92f9-f7cf7b39ce21 GET /v1/drugs/dd4446a6-58cb-498d-92f9-f7cf7b39ce21?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Plaster leczniczy",
"source": "urpl",
"strength": "700 mg",
"packaging": "05909991557904 ¦ Rp ¦ 158692\n5 plastrów\n05909991557911 ¦ Rp ¦ 158693\n10 plastrów\n05909991557928 ¦ Rp ¦ 158694\n20 plastrów\n05909991557935 ¦ Rp ¦ 158695\n25 plastrów\n05909991557942 ¦ Rp ¦ 158696\n30 plastrów",
"substance": "Lidocainum 700 mg",
"common_name": "Lidocainum",
"pl_product_id": "100507614",
"pozwolenie_nr": "378/24",
"auth_procedure": "IR",
"authorisation_validity": "2029-10-29"
}See everything about lidocaine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.